SANTA CLARA, Calif.–Affymetrix, Inc. (Nasdaq: AFFX) announced today the addition of Andrew J. Last, PhD, to its management team as Chief Commercial Officer.

“Andy is a proven leader in our core business as well as in the downstream markets of validation and routine testing,” said Kevin King, president and CEO of Affymetrix. “He will drive our commercial and product strategies, with responsibility for sales, marketing, and service. His skills and background are particularly useful as we continue to broaden our portfolio and extend our offerings to new customers.”

“Andy brings more than 25 years of global experience in the life science, pharmaceutical, diagnostics, and agrochemical industries and has held senior management positions at Monsanto, Incyte Genomics, Applied Biosystems, and Becton Dickinson.”

Prior to joining Affymetrix, Last served on the leadership team of BD Biosciences Cell Analysis Unit, where he was Vice President, Global Marketing & Strategic Planning and General Manager of the San Diego-based Pharmingen Business.

“Affymetrix is a powerful brand and innovative leader with technologies that are extremely well positioned to meet expanding market needs in multiple segments,” said Andy Last. “With the recent launch of new, enhanced platforms and a compelling strategy for the future, this is an exciting time for me to join the Affymetrix team. I look forward to leveraging my experience to help drive sustainable growth for the company.”

About Affymetrix

Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.

Forward-looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2008, and other SEC reports for subsequent quarterly periods.